Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WINDOCRE: Annual Versus Biannual Infusions of Ocrelizumab in Active MS
NCT05999604Phase 3Active, not recruiting
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Nov 2023
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ocrelizumab in multiple sclerosis (MS), sponsored by Adolphe de Rothschild Foundation Hospital. Started Nov 2023; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05999604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05999604.